The past five years or so have seen cannabinoids, led by THC and CBD, become immensely popular. While THC is responsible for marijuana’s intoxicating effects, CBD (cannabidiol) has shown a diverse range of possible medicinal properties. Most of the research is still in the preliminary stages; however, cannabidiol has been found to be effective against various symptoms ranging from anxiety and insomnia to chronic pain and epilepsy.
As CBD products became more accessible, some users noticed that full-spectrum CBD products that contain other minor cannabinoids, other than except for THC, and terpenes seemed to be more effective than CBD isolate products. In the wake of these claims, experts came up with a theory called the “entourage effect,” which states that the sum of all the chemical compounds in cannabis is better than a single cannabinoid taken on its own.
A new study by University of Sweden pharmacologists has uncovered clues on how this phenomenon, which they call the “pharmacokinetic entourage mechanism,” works, especially in regards to low-dose CBD products. According to the lead author of the study Dr. Lyndsey Anderson, cannabidiolic acid (“CBDA”) may have a greater role in the effects of low-dose CBD products.
CBDA has been found to reduce anxiety and seizures in preclinical trials, and it may very well be responsible for creating these effects when low-dose CBD products are consumed. CBDA, which is the precursor of CBD, turns into cannabidiol after the decarboxylation process. The study found that when users consume a full-spectrum CBD product, cannabinoids interact and produce cannabidiolic acid in much higher concentrations.
Compared to when CBDA was administered on its own, the full-spectrum CBD product delivered 14 times more CBDA in the bloodstream in animal trials using mice, says associate professor Jonathan Arnold with the Lambert Initiative for Cannabinoid Therapeutics. By interacting at specific transport proteins in the gut, Arnold says the range of cannabinoids in full-spectrum hemp extracts helped increase the rate of absorption of CBDA into the bloodstream. There has been little scientific proof to support the entourage effect since the theory first gained prominence, but this study has provided evidence showing that cannabinoids can interact and alter, among other things, their levels in the bloodstream, which will, in turn, affect how a CBD product will affect the user.
In this case, cannabinoids increase the levels as well as the rate of absorption of CBDA, which is known to reduce anxiety and seizures. Consequently, full-spectrum, low-dose CBD products appear to have the same anti-anxiety and anticonvulsant effects as cannabidiolic acid. The researchers, who published their study in Scientific Reports, will continue studying the entourage effect and learn how they can leverage its pharmaceutical potential.
If these findings are anything to go by, cannabis industry players such as Hero Technologies Inc. (OTC: HENC) are offering cannabis users a great service by manufacturing high-quality CBD and other cannabis products whose ingredients remain intact.
NOTE TO INVESTORS: The latest news and updates relating to Hero Technologies Inc. (OTC: HENC) are available in the company’s newsroom at https://cnw.fm/HENC
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.